Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 3/20 | 0.45 |
| ▸ | MDM4 | O15151 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | SIRT2 | Q8IXJ6 | 12/20 | 0.43 |
| ▸ | NMBR | P28336 | 1/20 | 0.40 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1737899 | 0.87 | MDM4 (0.54) | MDM4TP53SIRT2MDM2 | |
| SCHEMBL12994493 | 0.87 | MDM4 (0.54) | MDM4TP53SIRT2MDM2 | |
| SCHEMBL29368020 | 0.87 | MDM4 (0.54) | MDM4TP53SIRT2MDM2 | |
| SCHEMBL30433831 | 0.87 | MDM4 (0.54) | MDM4TP53SIRT2MDM2 | |
| SCHEMBL13227674 | 0.87 | MDM4 (0.54) | MDM4TP53SIRT2MDM2 | |
| SCHEMBL30468161 | 0.86 | SIRT2 (0.55) | MDM4TP53SIRT2NMBRMDM2 | |
| SCHEMBL18758112 | 0.84 | CASP3 (0.46) | CASP3MDM4TP53MDM2 | |
| SCHEMBL30385679 | 0.84 | MDM4 (0.49) | MDM4TP53SIRT2NMBRMDM2 | |
| SCHEMBL28625947 | 0.83 | MDM2 (0.52) | MDM4TP53SIRT2MDM2 | |
| SCHEMBL30434660 | 0.83 | MDM2 (0.52) | MDM4TP53SIRT2MDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025264177-A1 | METHOD FOR CLEAVING PROTECTING GROUPS AND ORGANIC COMPOUNDS FROM SUPPORTS | POLYPEPTIDE LABORATORIES HOLDING (PPL) AB (SE) | 2025-12-26 | — | — | WO | disclosed |
| US-12492225-B2 | Melanocyte-regulating peptides | IDP DISCOVERY PHARMA, S.L. (ES) | 2025-12-09 | — | — | US | disclosed |
| CN-119841893-A | Preparation method of polypeptide with anti-inflammatory effect | 兰树化妆品股份有限公司 | 2025-04-18 | — | — | CN | disclosed |
| EP-4532513-A1 | CYCLIC PEPTIDES WITH ANTIBACTERIAL ACTIVITY AGAINST MULTIDRUG RESISTANT (MDR) PATHOGENS | Fundación Privada Instituto De Salud Global Barcelona (ES) | 2025-04-09 | — | — | EP | disclosed |
| CN-119451974-A | Cyclic peptides having antibacterial activity against Multiple Drug Resistant (MDR) pathogens | 巴塞罗那全球健康研究所私人基金会 | 2025-02-14 | — | — | CN | disclosed |
| CN-118987168-A | Multifunctional active peptide and application thereof | 山东第二医科大学 | 2024-11-22 | — | — | CN | disclosed |
| US-20240294573-A1 | CONSTRAINED PEPTIDES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-09-05 | — | — | US | disclosed |
| US-20240083943-A1 | VEGF-REGULATING PEPTIDES | IDP DISCOVERY PHARMA, S.L. (ES) | 2024-03-14 | — | — | US | disclosed |
| WO-2023227771-A1 | CYCLIC PEPTIDES WITH ANTIBACTERIAL ACTIVITY AGAINST MULTIDRUG RESISTANT (MDR) PATHOGENS | Fundación Privada Instituto De Salud Global Barcelona (ES) | 2023-11-30 | — | — | WO | disclosed |
| EP-4271480-A1 | VEGF-REGULATING PEPTIDES | IDP Discovery Pharma, S.L. (ES) | 2023-11-08 | — | — | EP | disclosed |
| US-20220306708-A1 | BIFUNCTIONAL STAPLED POLYPEPTIDES AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2022-09-29 | — | — | US | disclosed |
| US-11440939-B2 | Anticancer peptides | IDP DISCOVERY PHARMA, S.L. (ES) | 2022-09-13 | — | — | US | disclosed |
| EP-4039698-A1 | PEPTIDES WITH ANTI-CANCER ACTIVITY | IDP Discovery Pharma, S.L. (ES) | 2022-08-10 | — | — | EP | disclosed |
| WO-2022144401-A1 | VEGF-REGULATING PEPTIDES | IDP DISCOVERY PHARMA, S.L. (ES) | 2022-07-07 | — | — | WO | disclosed |
| EP-4023295-A1 | VEGF-REGULATING PEPTIDES | IDP Discovery Pharma, S.L. (ES) | 2022-07-06 | — | — | EP | disclosed |
| EP-4007563-A1 | MELANOCYTE-REGULATING PEPTIDES | IDP Discovery Pharma, S.L. (ES) | 2022-06-08 | — | — | EP | disclosed |
| US-11352395-B2 | Anticancer peptides | IDP DISCOVERY PHARMA, S.L. (ES) | 2022-06-07 | — | — | US | disclosed |
| EP-3986914-A1 | CONSTRAINED PEPTIDES | TearSolutions, Inc. (US) | 2022-04-27 | — | — | EP | disclosed |
| CN-113717254-B | Antibacterial peptide and application thereof | 中山大学附属口腔医院 | 2022-03-22 | — | — | CN | disclosed |
| US-11279734-B2 | Solution-phase affinity selection of inhibitors from combinatorial peptide libraries | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2022-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12492225-B2 | Melanocyte-regulating peptides | MC1R, MITF, MCHR1 | CASP3 4704/4885MDM4 450/4885TP53 628/4885 |
| US-11440939-B2 | Anticancer peptides | NGLY1, SLC1A5, SSTR5 | CASP3 1352/4885MDM4 377/4885TP53 37/4885 |
| US-11279734-B2 | Solution-phase affinity selection of inhibitors from combinatorial peptide libraries | TP53, MDM2, MDM4 | CASP3 2615/4885MDM4 3/4885TP53 1/4885 |
| US-20240294573-A1 | CONSTRAINED PEPTIDES | IAPP, NGLY1, VIP | CASP3 1870/4885MDM4 2200/4885TP53 493/4885 |
| US-11352395-B2 | Anticancer peptides | PNISR, NGLY1, SLC1A5 | CASP3 2512/4885MDM4 265/4885TP53 124/4885 |
| US-20220306708-A1 | BIFUNCTIONAL STAPLED POLYPEPTIDES AND USES THEREOF | TIMCC, CCL2, SGTA | CASP3 2347/4885MDM4 2168/4885TP53 258/4885 |
| US-20240083943-A1 | VEGF-REGULATING PEPTIDES | VEGFA, FLT4, FLT1 | CASP3 3795/4885MDM4 662/4885TP53 294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.